Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

Identifieur interne : 001357 ( Main/Exploration ); précédent : 001356; suivant : 001358

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

Auteurs : Eamonn S. Molloy [Irlande (pays)] ; Leonard H. Calabrese [États-Unis]

Source :

RBID : ISTEX:3B8F75CB9F9E7EA1F98B6CAE895BD2989C4D7DC1

English descriptors

Abstract

Objective: To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases (ARDs). Methods: A Freedom of Information Act request was submitted for all cases of PML within the Food and Drug Administration Adverse Event Reporting System database. ARD cases were selected for further analysis. Results: A total of 34 confirmed cases of PML in the setting of ARDs were identified: 17 had systemic lupus erythematosus, 10 had rheumatoid arthritis, 4 had vasculitis, and 3 had dermatomyositis. Fifteen of these patients were treated with one or more biologic agents: 14 received rituximab (RTX), 6 received anti–tumor necrosis factor (anti‐TNF) therapy (5 treated with anti‐TNF agent prior to RTX). Four RTX‐treated patients were not receiving additional immunosuppressive therapy at the time of PML onset, other than an antimalarial drug and/or low‐dose glucocorticoids; all others who were receiving a biologic agent were also receiving one or more synthetic disease‐modifying agents. All but 1 patient receiving a biologic agent had at least 1 potential confounding factor for the diagnosis of PML. The remaining 19 confirmed cases of PML among ARD patients were treated with synthetic disease‐modifying antirheumatic drugs only, 14 of whom had received an alkylating agent. Conclusion: PML has been reported in patients with ARD treated with various immunosuppressive agents. The limitations of this study preclude definitive attribution of causality. While the paucity of confirmed cases recently exposed to anti‐TNF therapy suggests a causal relationship is unlikely, a specific signal is emerging with regard to rituximab and PML. Although this is a rare adverse event associated with RTX therapy, the devastating nature of PML mandates continued vigilance, particularly in patients with current or prior exposure to an alkylating agent.

Url:
DOI: 10.1002/art.34468


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies</title>
<author>
<name sortKey="Molloy, Eamonn S" sort="Molloy, Eamonn S" uniqKey="Molloy E" first="Eamonn S." last="Molloy">Eamonn S. Molloy</name>
</author>
<author>
<name sortKey="Calabrese, Leonard H" sort="Calabrese, Leonard H" uniqKey="Calabrese L" first="Leonard H." last="Calabrese">Leonard H. Calabrese</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3B8F75CB9F9E7EA1F98B6CAE895BD2989C4D7DC1</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1002/art.34468</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-GVWTS5LV-W/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000345</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000345</idno>
<idno type="wicri:Area/Istex/Curation">000345</idno>
<idno type="wicri:Area/Istex/Checkpoint">000366</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000366</idno>
<idno type="wicri:doubleKey">0004-3591:2012:Molloy E:progressive:multifocal:leukoencephalopathy</idno>
<idno type="wicri:Area/Main/Merge">001358</idno>
<idno type="wicri:Area/Main/Curation">001357</idno>
<idno type="wicri:Area/Main/Exploration">001357</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies</title>
<author>
<name sortKey="Molloy, Eamonn S" sort="Molloy, Eamonn S" uniqKey="Molloy E" first="Eamonn S." last="Molloy">Eamonn S. Molloy</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Irlande (pays)</country>
<wicri:regionArea>St. Vincent's University Hospital, Elm Park, Dublin</wicri:regionArea>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Irlande (pays)</country>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Irlande (pays)</country>
<wicri:regionArea>Correspondence address: Department of Rheumatology, St. Vincent's University Hospital, Elm Park, Dublin 4</wicri:regionArea>
<wicri:noRegion>Dublin 4</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Calabrese, Leonard H" sort="Calabrese, Leonard H" uniqKey="Calabrese L" first="Leonard H." last="Calabrese">Leonard H. Calabrese</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cleveland Clinic Foundation, Cleveland</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Arthritis & Rheumatism</title>
<title level="j" type="alt">ARTHRITIS AND RHEUMATISM</title>
<idno type="ISSN">0004-3591</idno>
<idno type="eISSN">1529-0131</idno>
<imprint>
<biblScope unit="vol">64</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="3043">3043</biblScope>
<biblScope unit="page" to="3051">3051</biblScope>
<biblScope unit="page-count">9</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2012-09">2012-09</date>
</imprint>
<idno type="ISSN">0004-3591</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0004-3591</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Aers</term>
<term>Aers database</term>
<term>Alkylating agent</term>
<term>Antiviral drugs</term>
<term>Ards</term>
<term>Arthritis rheum</term>
<term>Autoimmune</term>
<term>Biologic</term>
<term>Biologic agent</term>
<term>Biologic agents</term>
<term>Biologic therapies</term>
<term>Biopsy</term>
<term>Brain biopsy</term>
<term>Calabrese</term>
<term>Contrast enhancement</term>
<term>Cryoglobulinemic vasculitis</term>
<term>Database</term>
<term>Dermatomyositis</term>
<term>Drug administration</term>
<term>Erythematosus</term>
<term>Further analysis</term>
<term>Immunosuppressive</term>
<term>Immunosuppressive agents</term>
<term>Immunosuppressive therapy</term>
<term>Important drug warning</term>
<term>Inflammatory</term>
<term>Infliximab</term>
<term>Ivig</term>
<term>Last dose</term>
<term>Leukoencephalopathy</term>
<term>Lupus</term>
<term>Lymphoma</term>
<term>Lymphopenia</term>
<term>Magnetic resonance imaging</term>
<term>Medwatch forms</term>
<term>Mirt</term>
<term>Molloy</term>
<term>Multifocal</term>
<term>Mycophenolate mofetil</term>
<term>Natalizumab</term>
<term>Organ transplantation</term>
<term>Potential confounders</term>
<term>Progressive multifocal leukoencephalopathy</term>
<term>Rheumatic</term>
<term>Rheumatic diseases</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid vasculitis</term>
<term>Risk factors</term>
<term>Rituximab</term>
<term>Systemic lupus erythematosus</term>
<term>Transplantation</term>
<term>Vasculitis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Objective: To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases (ARDs). Methods: A Freedom of Information Act request was submitted for all cases of PML within the Food and Drug Administration Adverse Event Reporting System database. ARD cases were selected for further analysis. Results: A total of 34 confirmed cases of PML in the setting of ARDs were identified: 17 had systemic lupus erythematosus, 10 had rheumatoid arthritis, 4 had vasculitis, and 3 had dermatomyositis. Fifteen of these patients were treated with one or more biologic agents: 14 received rituximab (RTX), 6 received anti–tumor necrosis factor (anti‐TNF) therapy (5 treated with anti‐TNF agent prior to RTX). Four RTX‐treated patients were not receiving additional immunosuppressive therapy at the time of PML onset, other than an antimalarial drug and/or low‐dose glucocorticoids; all others who were receiving a biologic agent were also receiving one or more synthetic disease‐modifying agents. All but 1 patient receiving a biologic agent had at least 1 potential confounding factor for the diagnosis of PML. The remaining 19 confirmed cases of PML among ARD patients were treated with synthetic disease‐modifying antirheumatic drugs only, 14 of whom had received an alkylating agent. Conclusion: PML has been reported in patients with ARD treated with various immunosuppressive agents. The limitations of this study preclude definitive attribution of causality. While the paucity of confirmed cases recently exposed to anti‐TNF therapy suggests a causal relationship is unlikely, a specific signal is emerging with regard to rituximab and PML. Although this is a rare adverse event associated with RTX therapy, the devastating nature of PML mandates continued vigilance, particularly in patients with current or prior exposure to an alkylating agent.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Irlande (pays)</li>
<li>États-Unis</li>
</country>
<region>
<li>Ohio</li>
</region>
</list>
<tree>
<country name="Irlande (pays)">
<noRegion>
<name sortKey="Molloy, Eamonn S" sort="Molloy, Eamonn S" uniqKey="Molloy E" first="Eamonn S." last="Molloy">Eamonn S. Molloy</name>
</noRegion>
<name sortKey="Molloy, Eamonn S" sort="Molloy, Eamonn S" uniqKey="Molloy E" first="Eamonn S." last="Molloy">Eamonn S. Molloy</name>
<name sortKey="Molloy, Eamonn S" sort="Molloy, Eamonn S" uniqKey="Molloy E" first="Eamonn S." last="Molloy">Eamonn S. Molloy</name>
</country>
<country name="États-Unis">
<region name="Ohio">
<name sortKey="Calabrese, Leonard H" sort="Calabrese, Leonard H" uniqKey="Calabrese L" first="Leonard H." last="Calabrese">Leonard H. Calabrese</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001357 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001357 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3B8F75CB9F9E7EA1F98B6CAE895BD2989C4D7DC1
   |texte=   Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021